Clinical trial
Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine…
NCT00296829 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00296829 |
|---|---|
| Title | Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Orthomyxoviridae Infection, Influenza, Myxovirus Infection |
| Intervention type | Biological |
| Interventions | Inactivated, split-virion influenza vaccine |
| Enrollment | 1,080 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Feb 27, 2006 |
| Last update posted | Jan 14, 2014 |
| Countries | Australia, New Zealand |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: